Higher SGLT1 expression correlated with poorer clinical outcomes of EGFR TKI-treated NSCLC patients while targeting SGLT1 with pharmacological inhibitors suppressed enhancements in glucose metabolism and lowered acquisition of EGFR TKI resistance in NSCLC xenograft-bearing mice. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.